-
Iscalimab: Advancing Research in Autoimmune Diseases and Transplantation(Post)
What You Need to Know About IscalimabWhat is Iscalimab?Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key protein involved in immune system regulation.What is the mechanis
Naratuximab: Redefining Cancer Therapy with Precision Medicine(Post)Quick Facts About NaratuximabWhat is Naratuximab?Naratuximab is an anti-CD37 monoclonal antibody-drug conjugate (ADC) designed to target B-cell malignancies, particularly non-Hodgkin lym
HMGB1 in inflammation and cancer(Post)HMGB1 Functional Overview High mobility group box 1 ( HMGB1), a member of the high-mobility group (HMG) family, was first identified in the thymus in 1973 an
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest
Belantamab: A Game-Changer in Multiple Myeloma Therapy(Post)Quick Facts About BelantamabWhat is Belantamab?Belantamab Mafodotin is a cutting-edge antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory multiple myeloma.
Precio de kits ELISA: rangos reales y coste por ensayo(Post)Precio de kits ELISA: rangos reales y coste por ensayo El precio de un kit ELISA de 96 pocillos varía considerablemente según el fabricante, la validación y la aplicación, con ejemplos que muestran v
Neurofilament Light chain (NEFL) as a biomarker for neuronal damage(Post)Delve into the pivotal role of Neurofilament Light chain (NEFL) in neuron structure and its emerging importance as a biomarker for various neurodegenerative diseases, offering insights into dis
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research(Post)What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
Car t signalling pathway · H(Page) Mucosal Homing and Tissue-Resident Memory(Page) Siltuximab: Exploring IL-6 Inhibition in Castleman’s Disease and Research(Post)Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the m
Apoptosis Unveiled: Your Complete Guide to Intrinsic & Extrinsic Pathways(Post)Cell Biology · Programmed Cell DeathApoptosis: Your Complete Guide to Intrinsic & Extrinsic PathwaysApoptosis is programmed cell death — the controlled, non-inflammatory removal of damaged or unwanted
The common characteristics of cancer | Assay Genie(Post)By Shane Houston, PhD Candidate Queen’s University Belfast Cancer is an age old adversary of the human race. This out-of-control growth of abnormal cells has been a shadow over human health t
Avizakimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther
Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat
PI3K/AKT/mTOR Signalling in T Cells: Pathway, Function and Assays(Post)PI3K does not switch on a protein — it rewrites a membrane. Everything downstream follows from one chemical event: the 3-hydroxyl of a phosphoinositide is phosphorylated, PIP₂ becomes PIP₃, and every
T-cell receptor (TCR) signalling(Page) Coronavirus Assays(Page)Coronavirus Assays | SARS-CoV-2 ELISA, Multiplex, Rapid & PCR | Assay Genie
AKT Signalling – Mini Review(Post)Protein kinase B or AKT (PKB) is a serine/threonine kinase. In mammals it is comprised of 3 highly homologous isoforms PKBα (Akt1), PKBβ (Akt2), and PKBγ (Akt3) (Manning and Cantley 2007). AKT
Utomilumab: Advancing Immuno-Oncology Research(Post)Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.